Access cutting-edge functional dyspepsia treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Kansas City location
Preparing your pre-screening questions…
Access functional dyspepsia specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related functional dyspepsia treatment provided free
Check if you qualify for this functional dyspepsia clinical trial in Kansas City, MO
No-Cost Study Care
Local to Kansas City
Convenient for MO residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Acid reduction remains the most common treatment prescribed empirically by pediatric gastroenterologists for children with functional dyspepsia (FD). When acid reduction therapy fails to provide patients with a therapeutic effect, ketotifen and cromolyn, mast cell stabilizers, represent an attractive potential therapy given data implicating mast cells in the generation of dyspeptic symptoms. Although there have been no adult or pediatric studies on the use of mast cell stabilizers in patients with FD, benefit has been demonstrated in adults with IBS and children with eosinophilic gastroenteritis. Additionally, previous studies show mucosal eosinophilia is highly correlated with functional dyspepsia. Our usual current treatment pathway for functional dyspepsia in association with duodenal mucosal eosinophilia is as follows: acid-reducing medication/montelukast → addition of H1 antagonist → addition of budesonide → addition of oral cromolyn. If ketotifen is effective, it offers the advantage of being able to replace both the H1 antagonist and the oral cromolyn at a substantially reduced cost (approximately 10% of the cost of cromolyn alone). This study aims to introduce ketotifen earlier in the treatment pathway to examine its efficacy on children with functional dyspepsia in association with duodenal eosinophilia.
Sponsor: Craig A. Friesen, MD
Yes, this clinical trial (NCT02484248) has an active research site in Kansas City, MO that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for functional dyspepsia treatment options in Kansas City, MO, this clinical trial (NCT02484248) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced functional dyspepsia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all functional dyspepsia clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Kansas City — not just this study.
Browse Pulmonary Embolism Trials in Kansas City →